Echo Therapeutics' Needle-Free Prelude™ Drug Delivery System Is Featured in Fast Company Magazine

FRANKLIN, Mass., Feb. 10, 2011 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing the Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and the Prelude™ SkinPrep System for transdermal drug delivery, today announced that its needle-free drug delivery device, the Prelude System, is featured on the Fast Company magazine website.

The article headlined, "New Drug Delivery Device Will Speed Up Numbing, Sans Needle," notes that the Prelude System "promises to speed up the effects of lidocaine, a topical anesthetic, so shots, IVs, and other medical procedures will be less painful."  

"We are pleased to have our technology featured by Fast Company magazine and to have Prelude's needle-free drug delivery benefits explained so clearly to its influential readership," stated Patrick T. Mooney, MD, Chairman and CEO of Echo Therapeutics.  "Building on the positive momentum we have generated through much hard work, we are excited to increase the visibility of our needle-free platform technology as we near potential FDA marketing clearance."

The article also discussed the positive attributes for diabetics of Echo's Symphony System's non-invasive, wireless continuous transdermal glucose monitoring technology.

Fast Company magazine and Fastcompany.com are widely read business publications that cover innovation, technology and leadership, written by and for the most progressive business leaders.

About Echo Therapeutics

Echo Therapeutics has developed a platform technology for needle-free drug delivery as well as needle-free, continuous glucose monitoring.  It is developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals. Echo is also developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's and its partners' ongoing studies, including the efficacy of Echo's Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

Connect with Echo Therapeutics:

• Visit our website at www.echotx.com
• Follow us on Twitter at www.twitter.com/echotx
• Join us on Facebook at www.facebook.com/echotx

SOURCE Echo Therapeutics